The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - CellCarta

Dynamic changes of the immune infiltrate after neoadjuvant avelumab/axitinib in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy (NeoAvAx).
 
Axel Bex
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Speakers' Bureau - Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - Pfizer (Inst)
 
Yasmin Abu-Ghanem
No Relationships to Disclose
 
Johannes V. Van Thienen
No Relationships to Disclose
 
Niels Graafland
No Relationships to Disclose
 
Brunolf Lagerveld
No Relationships to Disclose
 
Patricia Zondervan
No Relationships to Disclose
 
Harrie Beerlage
No Relationships to Disclose
 
Jeroen van Moorselaar
No Relationships to Disclose
 
Mark Kockx
No Relationships to Disclose
 
Pieter-Jan Van Dam
Employment - CellCarta
 
Bernadett Szabados
No Relationships to Disclose
 
Christian U. Blank
Stock and Other Ownership Interests - Immagene; Uniti Cars
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); GenMab (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst); Third Rock Ventures
Research Funding - Bristol-Myers Squibb (Inst); NanoString Technologies (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Thomas Powles
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson; Merck; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson; Merck; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Research Funding - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Ipsen; Johnson & Johnson; Merck; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; MSD; Pfizer; Roche
 
John B. A. G. Haanen
Stock and Other Ownership Interests - Neogene Therapeutics
Consulting or Advisory Role - Achilles Therapeutics (Inst); AIMM Therapeutics (Inst); Bristol-Myers Squibb (Inst); Immunocore (Inst); Ipsen (Inst); Molecular Partners (Inst); MSD Oncology (Inst); Neogene Therapeutics; Neon Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Third Rock Ventures (Inst)
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Neon Therapeutics (Inst); Novartis (Inst)